Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Immunotherapy for metastatic colorectal cancer is effective only for mismatch repair-deficient
tumors with high microsatellite instability that demonstrate immune infiltration, suggesting …

Fluorouracil (5-FU) remains the first-line treatment for colorectal cancer (CRC). Although 5-
FU initially de-bulks the tumor mass, recurrence after chemotherapy is the barrier to effective …

Intratumoral heterogeneity is a major obstacle to cancer treatment and a significant
confounding factor in bulk-tumor profiling. We performed an unbiased analysis of …

Colorectal cancer is a heterogeneous disease that develops via stepwise accumulation of
well-characterized genetic and epigenetic alterations. We review the genetic changes …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Epithelial organoids recapitulate multiple aspects of real organs, making them promising
models of organ development, function and disease,,. However, the full potential of …